Bevacizumab and miR200c in Lung Cancer Resistance
Author Information
Author(s): Kobayashi Nobuaki, Katakura Seigo, Fukuda Nobuhiko, Somekawa Kohei, Kaneko Ayami, Kaneko Takeshi
Primary Institution: Yokohama City University Graduate School of Medicine
Hypothesis
This research aims to investigate the mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in non-small-cell lung cancer (NSCLC), particularly focusing on the role of the epithelial–mesenchymal transition (EMT) within the tumor microenvironment (TME).
Conclusion
The study provides insights into EMT-driven EGFR-TKI resistance in NSCLC and suggests potential strategies to overcome this resistance using Bevacizumab and miR200c.
Supporting Evidence
- The study identified a significant link between EMT and EGFR-TKI resistance.
- Bevacizumab showed promise in improving drug resistance and mitigating EMT.
- Transfection with miR200c was associated with improved EMT and drug resistance.
Takeaway
This study shows that a process called EMT helps lung cancer cells resist treatment, but using certain drugs can help make them more sensitive to treatment.
Methodology
The study used an in vitro three-dimensional organoid model to analyze EMT and drug resistance markers, evaluating the effects of Bevacizumab and miR200c.
Potential Biases
The study focused on specific EGFR mutations, which could bias the results.
Limitations
The organoid models do not fully replicate the human tumor microenvironment and may not accurately assess cancer cell-specific viability.
Participant Demographics
The study involved lung cancer cells with specific EGFR mutations (del 19 or L858R/T790M).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website